MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Halozyme Therapeutics Inc

Fermé

SecteurSoins de santé

61.86 -1.86

Résumé

Variation du prix de l'action

24h

Actuel

Min

61.13

Max

63.04

Chiffres clés

By Trading Economics

Revenu

1K

137M

Ventes

7.9M

298M

P/E

Moyenne du Secteur

18.604

63.778

BPA

1.26

Marge bénéficiaire

45.976

Employés

350

EBITDA

13M

203M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+7.11% upside

Dividendes

By Dow Jones

Prochains Résultats

6 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

690M

7.9B

Ouverture précédente

63.72

Clôture précédente

61.86

Sentiment de l'Actualité

By Acuity

50%

50%

180 / 386 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Halozyme Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

5 mars 2025, 19:42 UTC

Actualités

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

5 mars 2025, 10:30 UTC

Actualités

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

1 nov. 2024, 11:30 UTC

Actualités

S&P 500 Futures Climb In Premarket Trading; Atlassian, XP Lead

Comparaison

Variation de prix

Halozyme Therapeutics Inc prévision

Objectif de Prix

By TipRanks

7.11% hausse

Prévisions sur 12 Mois

Moyen 67.5 USD  7.11%

Haut 78 USD

Bas 53 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

8 ratings

5

Achat

3

Maintien

0

Vente

Score Technique

By Trading Central

62.85 / 63.8825Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

180 / 386Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.